Professor Sir Munir Pirmohamed - The NHS, the UK’s not so secret weapon in delivering Covid-19 research.
COVID-19 - the importance of embedding research and the clinical care interface as a whole, working seamlessly together, to improve future outcomes for patients. 

Transcript:https://docs.google.com/document/d/1tvGNL5rWd7t3NVbtWy1z8HJPzVPfZR9db-NgwmRCXf8/edit?usp=sharing

Professor Sir Munir Pirmohamed The NHS, UK's not so secret weapon in delivering Covid-19 research

Dr Emma Gray Assistant Director of Research at the MS Society 

Development of the multi-arm, multi-stage trial ‘Octopus’ for people with progressive MS
www.mssociety.org.uk/stop-ms

Transcript:https://docs.google.com/document/d/1kaoWeiRiZr7kZczP1omst2FvYWbwVun4VIN2MIzCHfU/edit?pli=1

Dr Emma Gray Development of the MAMS trial ‘Octopus’ for people with progressive MS

Professor of clinical oncology at the University of Oxford and Clinical Director of the Oxford Institute for Radiation Oncology - Stratified medicine studies: what we have learnt from the set-up and delivery of the adaptive FOCUS 4 trial.

Transcript: https://docs.google.com/document/d/1kkNeISk15owBsojhUk68ypHnUueDDcGnD6kv3by_L4w/edit

Professor Tim Maughan- Stratified medicine studies: lessons from running the adaptive FOCUS 4 trial.

Prof. Julie Lovegrove and Nutritional Research

Kelly Fricker is the lead research nurse at The Boathouse Surgery in Pangbourne, Reading. Here she speaks about what her role involves, studies into conditions such as arthritis and chronic obstructive pulmonary disease (COPD) and how her team are able to carry out research in their GP practice with the support of the National Institute for Health Research (NIHR).

Kelly Fricker: working as GP practice research nurse

Yan Yiannakou Clinical Director of the NIHR Patient Recruitment Centre – Newcastle 

Running a wholly virtual trial during the COVID19 pandemic.

Transcript: 
https://docs.google.com/document/d/1_HkW3ixWip1XtrqUAGeiinQX7J3divCC1tKo_X_HUWg/edit?usp=sharing

Yan Yiannakou - Running a wholly virtual trial during the COVID-19 pandemic.

Dr Kirsty Wydenbach deputy unit manager and senior medical assessor at the clinical trials unit in the MHRA

Challenges and advice for complex innovative design trials, and how COVID-19 has impacted on the MHRAs approach.

Transcript:https://docs.google.com/document/d/1HS-c3mR-B4m3RCtRpWHb5kIS8Xv90XJ2IIReWOg4fpw/edit?usp=sharing

Kirsty Wydenbach Challenges and advice for CID  trials, and how COVID-19 has impacted the MHRA.

Dr Camille Carroll Associate Professor and Honorary Consultant Neurologist Peninsula Medical School (Faculty of Health). NSL for Neurology NIHR CRN

The role of digital technology, such as sensors and wearables, in clinical trials.

Transcript https://docs.google.com/document/d/1OwnBt7efXXCn3-DpefjIukDHtrrXYzEg9XmzXfhZQoc/edit?usp=sharing

Dr Camille Carroll - The role of digital technology, in clinical trials.

Professor Thomas Jaki - Professor of Statistics at Lancaster University and Programme Leader at the MRC Biostatistics Unit at the University of Cambridge

The AGILE initiative and the advantages and challenges of Platform Trials.

Transcript: https://docs.google.com/document/d/1ad6R8yTfRsdna7Wk442ybKHwPB4h5oZF3WzUqqEMubw/edit?usp=sharing

Professor Thomas Jaki - The AGILE initiative and the advantages and challenges of Platform Trials.

Matt Sydes Professor of Clinical Trials and Methodology at the MRC Clinical Trials Unit at University College London.
 
The importance of communicating trial results to the study participants.

Transcript:https://docs.google.com/document/d/1_tCdh1o9gWFsu5yXeTyXf8JDozGWF4qNrVTspeWNoFA/edit?usp=sharing

Professor Matt Sydes - The importance of communicating trial results to the study participants.

Emma Lowe - acting head of research policy for clinical research and growth at the UK department of health and social care (DHSC) - focus on the Innovation in delivery of research studies during the COVID pandemic.
Transcript: https://docs.google.com/document/d/13XO3AK7ar2co34e0zT-jPWZ-iI88xavLaqzXo0O09DE/edit?usp=sharing

Emma Lowe -  Innovation in clinical research during the COVID pandemic

Following on from our first round of podcasts that evolved from the recommendations in the paper; Effective delivery of Complex Innovative Design (CID) cancer trials- a consensus statement focusing on complex innovative design trials the NIHR CRN coordinating center has again collaborated with the Health Research Authority and in this series, the NIHR Office for Clinical Research Infrastructure. This time, we will be discussing some of the key learning points from the COVID-19 pandemic, such as: -
Has the recent success using innovative design and delivery of research studies during the COVID pandemic been part due to the advance of innovation in trials pre-COVID-19?
Could Continuous Improvement mean innovation in COVID-19 research inform studies post the pandemic? And how can we evidence this?
The general learnings and happenings throughout the COVID-19 pandemic, and we will be building on the further questions around the management and delivery of innovative design trials during the pandemic.
From Weds 27th January we will roll out a weekly podcast here aimed at anyone with an interest in designing, delivering or reviewing Innovation in Trail Design and Study Delivery. They are presented by experienced research professionals from across the research environment.
The research delivery infrastructure in the UK provided by the NIHR, working closely with the NHS, regulators and stakeholders, continues to deliver unparalleled clinical research activity to address the COVID-19 pandemic. Agility, coordination and innovation are core attributes that are driving this impact made by our clinical research. They are also attributes that will ensure the UK can regrow the comprehensive health and social care research portfolio as soon as the harm of the COVID-19 pandemic upon health and social care is overcome. Drawing upon proven research infrastructure and our culture of continuous improvement from recent experience (such as those shared in this podcast series) provides this platform for future success.

Trailer - Innovation in Trial Design and Study Delivery during the COVID pandemic Podcast Series II

Professor Pam Kearns, Director of the Cancer Research UK Clinical Trials Unit,  University of Birmingham  
 
The CATALYST trial: Accelerating drug development for COVID-19

Transcript: https://docs.google.com/document/d/1h5c5C15kiTqsPEJPoHXkbcDTD_hbhIBNzSQjQavteLk/edit?usp=sharing

Professor Pam Kearns - The CATALYST trial: Accelerating drug development for COVID-19

Dr Hugh Davies chair of the Oxford research ethics committee and was formerly a research ethics advisor to the health research authority. Dr. Davies trained in medicine and was a consultant paediatrician for many years.

Transcript: https://docs.google.com/document/d/1JJR0JF_1jPKOoxN45M-xZtD8obbEWd9S3ezHKR5f-K0/edit?usp=sharing

Dr Hugh Davies How the C-19 pandemic & clinical experience can be a new preface to clinical research

The National Institute for Health and Care Research (NIHR): funding, enabling and delivering world-class health and care research that transforms people's lives. Visit our website: www.nihr.ac.uk

For our latest podcasts please visit our new page: https://www.buzzsprout.com/1833774/episodes

Popular tracks by National Institute for Health and Care Research